A Phase 1 interventional study of Nerandomilast 18 mg - adult formulation and Nerandomilast 1 mg - paediatric formulation in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this trial is to investigate two different formulations of nerandomilast and the effect of food on the pharmacokinetics of the new formulation following oral administration.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants first received a single oral dose of 1 tablet of 18 milligrams (mg) nerandomilast adult formulation in the fasted state (Reference treatment, R), followed by a single oral dose of 18 tablets of 1 mg nerandomilast pediatric formulation in the fasted state (Treatment, T1), and then 18 tablets of 1 mg of nerandomilast pediatric formulation in the fed state as a single oral dose (Treatment, T2). Treatments were separated by a wash-out period of at least 7 days and treatments were taken with 240 mL of water after an overnight fast of at least 10 hours (hrs) for R and T1, or after a high-fat, high-calorie breakfast for T2.
Drug: Nerandomilast 18 mg - adult formulation · Drug: Nerandomilast 1 mg - paediatric formulation
Participants first received a single oral dose of 18 tablets of 1 mg nerandomilast pediatric formulation in the fasted state (T1), followed by a single oral dose of 18 tablets of 1 mg nerandomilast pediatric formulation in the fed state (T2), and then a single oral dose of 18 mg of nerandomilast adult formulation in the fasted state (R). Treatments were separated by a wash-out period of at least 7 days and treatments were taken with 240 mL of water after an overnight fast of at least 10 hrs for R and T1, or after a high-fat, high-calorie breakfast for T2.
Drug: Nerandomilast 18 mg - adult formulation · Drug: Nerandomilast 1 mg - paediatric formulation
Participants first received a single oral dose of 18 tablets of 1 mg nerandomilast pediatric formulation in the fed state (T2), followed by a single oral dose of 18 mg of nerandomilast adult formulation in the fasted state (R), and then a single oral dose of 18 tablets of 1 mg nerandomilast pediatric formulation in the fasted state (T1). Treatments were separated by a wash-out period of at least 7 days and treatments were taken with 240 mL of water after an overnight fast of at least 10 hrs for R and T1, or after a high-fat, high-calorie breakfast for T2.
Drug: Nerandomilast 18 mg - adult formulation · Drug: Nerandomilast 1 mg - paediatric formulation
BI 1015550, oral tablet
Also known as: BI 1015550, JASCAYD®
BI 1015550, oral tablet
Also known as: BI 1015550, JASCAYD®
AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T1 vs Reference R
AUC0-tz (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 to the last quantifiable data point) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% confidence interval (CI).
Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T2 vs T1
AUC0-tz (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 to the last quantifiable data point) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.
Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
Cmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T1 vs Reference R
Cmax (maximum measured concentration of nerandomilast in plasma) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.
Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
Cmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T2 vs T1
Cmax (maximum measured concentration of nerandomilast in plasma) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.
Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
AUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T1 vs Reference R
AUC0-∞ (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.
Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
AUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T2 vs T1
AUC0-∞ (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.
Time frame: Within 3 hours (hrs) before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 58, 72, and 96 hrs after drug administration. For dosing after 58hrs, a tolerance of +/- 2 hrs was allowed.
This trial was an open-label, single dose, 3-way crossover design. Subjects were randomly allocated to one of 3 treatment sequences. Each subject participated in 3 treatment periods, receiving a single dose in each, with a washout period of at least 7 days between treatments.
| Milestone | Nerandomilast (18 mg) in Treatment Sequence R-T1-T2 | Nerandomilast (18 mg) in Treatment Sequence T1-T2-R | Nerandomilast (18 mg) in Treatment Sequence T2-R-T1 |
|---|---|---|---|
| Started | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 |
| Milestone | Nerandomilast (18 mg) in Treatment Sequence R-T1-T2 | Nerandomilast (18 mg) in Treatment Sequence T1-T2-R | Nerandomilast (18 mg) in Treatment Sequence T2-R-T1 |
|---|---|---|---|
| Started | 5 | 5 | 5 |
| Completed | 5 | 5 | 4 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Milestone | Nerandomilast (18 mg) in Treatment Sequence R-T1-T2 | Nerandomilast (18 mg) in Treatment Sequence T1-T2-R | Nerandomilast (18 mg) in Treatment Sequence T2-R-T1 |
|---|---|---|---|
| Started | 5 | 5 | 4 |
| Completed | 5 | 5 | 4 |
| Not completed | 0 | 0 | 0 |
| Milestone | Nerandomilast (18 mg) in Treatment Sequence R-T1-T2 | Nerandomilast (18 mg) in Treatment Sequence T1-T2-R | Nerandomilast (18 mg) in Treatment Sequence T2-R-T1 |
|---|---|---|---|
| Started | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 |
| Milestone | Nerandomilast (18 mg) in Treatment Sequence R-T1-T2 | Nerandomilast (18 mg) in Treatment Sequence T1-T2-R | Nerandomilast (18 mg) in Treatment Sequence T2-R-T1 |
|---|---|---|---|
| Started | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 |
AUC0-tz (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 to the last quantifiable data point) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% confidence interval (CI).
| hours*nanomoles/Liter (h·nmol/L) | Nerandomilast 18 mg Pediatric (Ped) Fasted State (Treatment T1) | Nerandomilast 18 mg Adult Fasted State (Reference R) |
|---|---|---|
| AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T1 vs Reference R | 2732.81 ± NA | 2647.2 ± NA |
AUC0-tz (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 to the last quantifiable data point) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.
| hours*nanomoles/Liter (h·nmol/L) | Nerandomilast 18 mg Ped Fed State (Treatment T2) | Nerandomilast 18 mg Ped Fasted State (Treatment T1) |
|---|---|---|
| AUC0-tz (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Treatment T2 vs T1 | 2611.55 ± NA | 2732.81 ± NA |
Cmax (maximum measured concentration of nerandomilast in plasma) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.
| nanomoles/Liter (nmol/L) | Nerandomilast 18 mg Ped Fasted State (Treatment T1) | Nerandomilast 18 mg Adult Fasted State (Reference R) |
|---|---|---|
| Cmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T1 vs Reference R | 501.74 ± NA | 480.85 ± NA |
Cmax (maximum measured concentration of nerandomilast in plasma) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.
| nanomoles/Liter (nmol/L) | Nerandomilast 18 mg Ped Fed State (Treatment T2) | Nerandomilast 18 mg Ped Fasted State (Treatment T1) |
|---|---|---|
| Cmax (Maximum Measured Concentration of Nerandomilast in Plasma) for Treatment T2 vs T1 | 344.76 ± NA | 501.74 ± NA |
AUC0-∞ (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity) for Treatment T1 vs Reference R is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.
| hours*nanomoles/Liter (h·nmol/L) | Nerandomilast 18 mg Pediatric (Ped) Fasted State (Treatment T1) | Nerandomilast 18 mg Adult Fasted State (Reference R) |
|---|---|---|
| AUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T1 vs Reference R | 2748.78 ± NA | 2667.20 ± NA |
AUC0-∞ (area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity) for Treatment T2 vs T1 is reported. Geometric least square mean (adjusted geometric mean) and standard error (adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale restricted to the data of interest for each comparison. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effect 'subjects within sequences' as random and the other effects of sequence, period and treatment were considered as fixed. These quantities were then back-transformed to the original scale to provide the point estimate and the 90% CI.
| hours*nanomoles/Liter (h·nmol/L) | Nerandomilast 18 mg Ped Fed State (Treatment T2) | Nerandomilast 18 mg Ped Fasted State (Treatment T1) |
|---|---|---|
| AUC0-∞ (Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity) for Treatment T2 vs T1 | 2631.39 ± NA | 2748.78 ± NA |
Collected over Adverse events: From intake of trial medication till end of the residual effect period (REP), up to 7 days for each treatment. All-Cause Mortality: Up to 7 days (REP) for each treatment (R, T1, T2), then follow-up (13 days), up to a total of 34 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nerandomilast 18 mg Adult Fasted State (Reference R) | 0/14 (0%) | 0/14 (0%) | 6/14 (42.9%) |
| Nerandomilast 18 mg Ped Fasted State (Treatment T1) | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| Nerandomilast 18 mg Ped Fed State (Treatment T2) | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| Event | Nerandomilast 18 mg Adult Fasted State (Reference R) | Nerandomilast 18 mg Ped Fasted State (Treatment T1) | Nerandomilast 18 mg Ped Fed State (Treatment T2) |
|---|---|---|---|
| HeadacheNervous system disorders | 4/14 | 7/15 | 6/15 |
| NauseaGastrointestinal disorders | 2/14 | 2/15 | 2/15 |
| DizzinessNervous system disorders | 2/14 | 0/15 | 0/15 |
| Abdominal distensionGastrointestinal disorders | 0/14 | 2/15 | 1/15 |
| VomitingGastrointestinal disorders | 0/14 | 0/15 | 2/15 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/14 | 2/15 | 0/15 |
| Skin lesionSkin and subcutaneous tissue disorders | 0/14 | 2/15 | 0/15 |
| ConstipationGastrointestinal disorders | 1/14 | 0/15 | 0/15 |
| FatigueGeneral disorders | 1/14 | 0/15 | 0/15 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/14 | 0/15 | 0/15 |
Treated set (TS): The treated set included all subjects who were treated with at least one dose of trial drug. The number of subjects reported in each arm represents the number of subjects who took the first treatment in the respective sequence.
| Age, Continuous(Years) | Nerandomilast (18 mg) in Treatment Sequence R-T1-T2 | Nerandomilast (18 mg) in Treatment Sequence T1-T2-R | Nerandomilast (18 mg) in Treatment Sequence T2-R-T1 | Total |
|---|---|---|---|---|
| Mean | 40.2 ± 10.5 | 37.8 ± 10.1 | 39.8 ± 8.6 | 39.3 ± 9.1 |
| Sex: Female, Male(Participants) | Nerandomilast (18 mg) in Treatment Sequence R-T1-T2 | Nerandomilast (18 mg) in Treatment Sequence T1-T2-R | Nerandomilast (18 mg) in Treatment Sequence T2-R-T1 | Total |
|---|---|---|---|---|
| Female | 4 | 3 | 5 | 12 |
| Male | 1 | 2 | 0 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Nerandomilast (18 mg) in Treatment Sequence R-T1-T2 | Nerandomilast (18 mg) in Treatment Sequence T1-T2-R | Nerandomilast (18 mg) in Treatment Sequence T2-R-T1 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 5 | 5 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Nerandomilast (18 mg) in Treatment Sequence R-T1-T2 | Nerandomilast (18 mg) in Treatment Sequence T1-T2-R | Nerandomilast (18 mg) in Treatment Sequence T2-R-T1 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 5 | 5 | 5 | 15 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Oct 2024 to primary completion in Nov 2024, 1 month.
Results were first posted in Jan 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nerandomilast